{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Intramuscular+vaccine&page=15",
    "query": {
      "intervention": "Intramuscular vaccine",
      "page": 15
    },
    "page_size": 10
  },
  "pagination": {
    "page": 15,
    "page_size": 10,
    "total_count": 835,
    "total_pages": 84,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Intramuscular+vaccine&page=16&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Intramuscular+vaccine&page=14&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-11-15T15:02:38.880Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT05141721",
      "title": "A Study of a Patient-Specific Neoantigen Vaccine in Combination With Immune Checkpoint Blockade for Patients With Metastatic Colorectal Cancer",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2",
        "PHASE3"
      ],
      "conditions": [
        "Colorectal Neoplasms"
      ],
      "interventions": [
        {
          "name": "GRT-C901",
          "type": "DRUG"
        },
        {
          "name": "GRT-R902",
          "type": "DRUG"
        },
        {
          "name": "Atezolizumab",
          "type": "DRUG"
        },
        {
          "name": "Ipilimumab",
          "type": "DRUG"
        },
        {
          "name": "Fluoropyrimidine plus leucovorin",
          "type": "DRUG"
        },
        {
          "name": "Bevacizumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Seattle Project Corporation",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 700,
      "start_date": "2022-02-12",
      "completion_date": "2027-03",
      "has_results": false,
      "last_update_posted_date": "2025-05-16",
      "last_synced_at": "2026-11-15T15:02:38.880Z",
      "location_count": 43,
      "location_summary": "Gilbert, Arizona • Springdale, Arkansas • Los Angeles, California + 36 more",
      "locations": [
        {
          "city": "Gilbert",
          "state": "Arizona"
        },
        {
          "city": "Springdale",
          "state": "Arkansas"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Orange",
          "state": "California"
        },
        {
          "city": "Santa Monica",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05141721"
    },
    {
      "nct_id": "NCT05901636",
      "title": "A Clinical Study to Evaluate an Experimental Universal Influenza Vaccine, INFLUENZA G1 mHA, in Healthy Adults",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Influenza Prevention"
      ],
      "interventions": [
        {
          "name": "INFLUENZA G1 mHA",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Al(OH)3",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Janssen Vaccines & Prevention B.V.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "45 Years",
        "sex": "ALL",
        "summary": "18 Years to 45 Years"
      },
      "enrollment_count": 170,
      "start_date": "2023-05-17",
      "completion_date": "2024-08-19",
      "has_results": true,
      "last_update_posted_date": "2025-09-08",
      "last_synced_at": "2026-11-15T15:02:38.880Z",
      "location_count": 4,
      "location_summary": "Miami Lakes, Florida • Lenexa, Kansas • Metairie, Louisiana + 1 more",
      "locations": [
        {
          "city": "Miami Lakes",
          "state": "Florida"
        },
        {
          "city": "Lenexa",
          "state": "Kansas"
        },
        {
          "city": "Metairie",
          "state": "Louisiana"
        },
        {
          "city": "Cincinnati",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05901636"
    },
    {
      "nct_id": "NCT00258895",
      "title": "Safety and Immunogenicity of DAPTACEL® as 5th Dose in Children 4 to 6 Years Old After 4 Doses of Pentacel™ or DAPTACEL®",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Diphtheria",
        "Tetanus",
        "Pertussis"
      ],
      "interventions": [
        {
          "name": "DAPTACEL®: DTaP",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Sanofi Pasteur, a Sanofi Company",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "4 Years",
        "maximum_age": "6 Years",
        "sex": "ALL",
        "summary": "4 Years to 6 Years"
      },
      "enrollment_count": 649,
      "start_date": "2005-03",
      "completion_date": "2007-04",
      "has_results": true,
      "last_update_posted_date": "2016-04-14",
      "last_synced_at": "2026-11-15T15:02:38.880Z",
      "location_count": 22,
      "location_summary": "Fayetteville, Arkansas • Jonesboro, Arkansas • Little Rock, Arkansas + 18 more",
      "locations": [
        {
          "city": "Fayetteville",
          "state": "Arkansas"
        },
        {
          "city": "Jonesboro",
          "state": "Arkansas"
        },
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "Fountain Valley",
          "state": "California"
        },
        {
          "city": "Centennial",
          "state": "Colorado"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00258895"
    },
    {
      "nct_id": "NCT01711645",
      "title": "Tdap Vaccine in Post-Partum Women",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Diphtheria",
        "Pertussis",
        "Tetanus"
      ],
      "interventions": [
        {
          "name": "Tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccine adsorbed onto aluminum phosphate",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "45 Years",
        "sex": "FEMALE",
        "summary": "18 Years to 45 Years · Female only"
      },
      "enrollment_count": 55,
      "start_date": "2012-10-26",
      "completion_date": "2015-08-28",
      "has_results": true,
      "last_update_posted_date": "2017-05-05",
      "last_synced_at": "2026-11-15T15:02:38.880Z",
      "location_count": 1,
      "location_summary": "Nashville, Tennessee",
      "locations": [
        {
          "city": "Nashville",
          "state": "Tennessee"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01711645"
    },
    {
      "nct_id": "NCT06905275",
      "title": "A Clinical Trial to Evaluate the Safety and Immunogenicity of Glycan-trimmed HIV-1 Nanoparticle Vaccine (UVAX-1107), Followed by Homologous or Wild-type HIV-1 Nanoparticle Vaccine (UVAX-1197) Boost, Each Adjuvanted With 3M-052-AF + Alum in Adult Participants Without HIV",
      "overall_status": "SUSPENDED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "HIV-1-infection"
      ],
      "interventions": [
        {
          "name": "3M-052-AF + Alum",
          "type": "BIOLOGICAL"
        },
        {
          "name": "UVAX-1107",
          "type": "BIOLOGICAL"
        },
        {
          "name": "UVAX-1197",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)",
      "sponsor_class": "NIH",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "18 Years to 55 Years"
      },
      "enrollment_count": 25,
      "start_date": "2025-07-07",
      "completion_date": "2027-07-20",
      "has_results": false,
      "last_update_posted_date": "2025-09-04",
      "last_synced_at": "2026-11-15T15:02:38.880Z",
      "location_count": 4,
      "location_summary": "Birmingham, Alabama • New York, New York • Rochester, New York + 1 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "New York",
          "state": "New York"
        },
        {
          "city": "Rochester",
          "state": "New York"
        },
        {
          "city": "Nashville",
          "state": "Tennessee"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06905275"
    },
    {
      "nct_id": "NCT07805707",
      "title": "A Study on the Efficacy of a Vaccine Against Influenza in Adults ≥65 Years of Age",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Influenza, Human"
      ],
      "interventions": [
        {
          "name": "mRNA Seasonal Flu vaccine",
          "type": "COMBINATION_PRODUCT"
        },
        {
          "name": "Licensed Influenza Vaccine",
          "type": "COMBINATION_PRODUCT"
        }
      ],
      "intervention_types": [
        "COMBINATION_PRODUCT"
      ],
      "sponsor": "GlaxoSmithKline",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "65 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "65 Years and older"
      },
      "enrollment_count": 54000,
      "start_date": "2026-09-02",
      "completion_date": "2028-06-09",
      "has_results": false,
      "last_update_posted_date": "2026-09-18",
      "last_synced_at": "2026-11-15T15:02:38.880Z",
      "location_count": 161,
      "location_summary": "Anniston, Alabama • Guntersville, Alabama • Glendale, Arizona + 128 more",
      "locations": [
        {
          "city": "Anniston",
          "state": "Alabama"
        },
        {
          "city": "Guntersville",
          "state": "Alabama"
        },
        {
          "city": "Glendale",
          "state": "Arizona"
        },
        {
          "city": "Mesa",
          "state": "Arizona"
        },
        {
          "city": "Mesa",
          "state": "Arizona"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07805707"
    },
    {
      "nct_id": "NCT05525546",
      "title": "Salmonella Conjugates CVD 2000: Study of Responses to Vaccination With Trivalent Salmonella Conjugate Vaccine to Prevent Invasive Salmonella Disease",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Risk Reduction"
      ],
      "interventions": [
        {
          "name": "Trivalent Salmonella Conjugate Vaccine (TSCV) Full-Strength Formulation",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Trivalent Salmonella Conjugate Vaccine (TSCV) Half-Strength Formulation",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Trivalent Salmonella Conjugate Vaccine (TSCV) Dilutional Half-Strength Formulation",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "OTHER"
      ],
      "sponsor": "University of Maryland, Baltimore",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "49 Years",
        "sex": "ALL",
        "summary": "18 Years to 49 Years"
      },
      "enrollment_count": 82,
      "start_date": "2022-08-15",
      "completion_date": "2023-06-12",
      "has_results": false,
      "last_update_posted_date": "2023-09-21",
      "last_synced_at": "2026-11-15T15:02:38.880Z",
      "location_count": 1,
      "location_summary": "Baltimore, Maryland",
      "locations": [
        {
          "city": "Baltimore",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05525546"
    },
    {
      "nct_id": "NCT03743688",
      "title": "Kinetics of the Immune Response to Inactivated Influenza Vaccine in Healthy Adults",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Influenza",
        "Influenza, Human",
        "Vaccine Reaction",
        "Influenza A",
        "Influenza Type B",
        "Influenza A H1N1",
        "Influenza A H3N2"
      ],
      "interventions": [
        {
          "name": "Influenza Vaccine Recipients",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Vanderbilt University Medical Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "45 Years",
        "sex": "ALL",
        "summary": "18 Years to 45 Years"
      },
      "enrollment_count": 10,
      "start_date": "2018-12-04",
      "completion_date": "2019-07-26",
      "has_results": false,
      "last_update_posted_date": "2019-08-05",
      "last_synced_at": "2026-11-15T15:02:38.880Z",
      "location_count": 1,
      "location_summary": "Nashville, Tennessee",
      "locations": [
        {
          "city": "Nashville",
          "state": "Tennessee"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03743688"
    },
    {
      "nct_id": "NCT06436703",
      "title": "A Study About Modified RNA Vaccines Against Influenza in Healthy Adults",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Influenza, Human"
      ],
      "interventions": [
        {
          "name": "Influenza ModRNA Vaccine",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Quadrivalent Influenza Vaccine (QIV)",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Pfizer",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 1202,
      "start_date": "2024-05-23",
      "completion_date": "2025-02-05",
      "has_results": true,
      "last_update_posted_date": "2026-06-12",
      "last_synced_at": "2026-11-15T15:02:38.880Z",
      "location_count": 32,
      "location_summary": "Mobile, Alabama • Scottsdale, Arizona • Anaheim, California + 25 more",
      "locations": [
        {
          "city": "Mobile",
          "state": "Alabama"
        },
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "Anaheim",
          "state": "California"
        },
        {
          "city": "Lake Forest",
          "state": "California"
        },
        {
          "city": "San Diego",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06436703"
    },
    {
      "nct_id": "NCT05077137",
      "title": "A Feasibility Study Utilizing Immune Recall to Increase Response to Checkpoint Therapy",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Melanoma"
      ],
      "interventions": [
        {
          "name": "Tetanus Diptheria Vaccine",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Polio Boost Immunization",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Duke University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 25,
      "start_date": "2021-09-07",
      "completion_date": "2027-07-01",
      "has_results": false,
      "last_update_posted_date": "2026-11-06",
      "last_synced_at": "2026-11-15T15:02:38.880Z",
      "location_count": 1,
      "location_summary": "Durham, North Carolina",
      "locations": [
        {
          "city": "Durham",
          "state": "North Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05077137"
    }
  ]
}